🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 08861T206 (prev. 08861T107 )
- Market Cap
- Micro Cap · $14 Million
- IPO
- 2/3/2015 · $7.00/share
Business: BG Medicine, Inc., the developer of the BGM Galectin-3 Test, is focused on the development and delivery of diagnostic solutions to aid in the clinical management of heart failure and related disorders. Galectin-3 is a protein that is involved in fundamental disease processes, including the development of fibrosis in organ tissues and cardiac remodeling, which may lead to the development and progression of heart failure.
Notes: Sept. 15, 2015 -- The Company today announced that on September 14, 2015, the Company was notified by The NASDAQ Stock Market LLC that trading in the Company's common stock will be suspended on NASDAQ effective with the open of business on Wednesday, September 16, 2015, due to the Company's continuing non-compliance with the stockholders' equity requirement set forth in NASDAQ Listing Rule. The Company expects its common stock to begin trading on the OTC Market's OTCQB market tier effective with the open of business on September 16, 2015 under its current trading symbol BGMD. __________________ July 8, 2015 -- BG Medicine, Inc. Common Stock (BGMD) will effect a one for four (1-4) reverse stock split of its outstanding common stock. The reverse split will be effective at the opening of business on Thursday, July 9, 2015. In conjunction with the reverse split, the CUSIP number will change to 08861T206.
Company Contact
- CEO
- Paul R. Sohmer
- CFO
- Stephen Hall
- Headquarters
- 303 Wyman Street, Suite 300, Waltham, MA 02451
- Phone
- 781-890-1199
- Fax
- 781-895-1119
- Investor Relations
- 781-434-0204 · investor@bg-medicine.com